Published in Brain on April 24, 2006
Protective effects of recombinant osteopontin on early brain injury after subarachnoid hemorrhage in rats. Crit Care Med (2010) 1.78
Selective neuronal loss in ischemic stroke and cerebrovascular disease. J Cereb Blood Flow Metab (2013) 1.19
Possible functional links among brain- and skull-related genes selected in modern humans. Front Psychol (2015) 0.89
Senescence-accelerated Mice (SAMs) as a Model for Brain Aging and Immunosenescence. Aging Dis (2011) 0.88
Increased brain damage after ischaemic stroke in mice lacking the chemokine receptor CCR5. Br J Pharmacol (2010) 0.88
Characterization of osteopontin expression and function after status epilepticus. Epilepsia (2008) 0.83
Osteopontin is not critical for otoconia formation or balance function. J Assoc Res Otolaryngol (2008) 0.82
Osteopontin mediates survival, proliferation and migration of neural stem cells through the chemokine receptor CXCR4. Stem Cell Res Ther (2015) 0.81
Osteopontin expression and function within the dorsal root ganglion. Neuroreport (2007) 0.81
Mice lacking the β2 adrenergic receptor have a unique genetic profile before and after focal brain ischaemia. ASN Neuro (2012) 0.80
The effect of osteopontin and osteopontin-derived peptides on preterm brain injury. J Neuroinflammation (2014) 0.80
Progressive secondary neurodegeneration and microcalcification co-occur in osteopontin-deficient mice. Am J Pathol (2010) 0.80
Glucose consumption of inflammatory cells masks metabolic deficits in the brain. Neuroimage (2015) 0.79
Sustained expression of osteopontin is closely associated with calcium deposits in the rat hippocampus after transient forebrain ischemia. J Histochem Cytochem (2012) 0.78
Osteopontin is induced by TGF-β2 and regulates metabolic cell activity in cultured human optic nerve head astrocytes. PLoS One (2014) 0.77
Mouse mutants for the nicotinic acetylcholine receptor ß2 subunit display changes in cell adhesion and neurodegeneration response genes. PLoS One (2011) 0.77
Osteogenesis and neurogenesis: a robust link also for language evolution. Front Cell Neurosci (2015) 0.77
Recombinant Osteopontin Stabilizes Smooth Muscle Cell Phenotype via Integrin Receptor/Integrin-Linked Kinase/Rac-1 Pathway After Subarachnoid Hemorrhage in Rats. Stroke (2016) 0.76
Osteopontin expression in the brain triggers localized inflammation and cell death when immune cells are activated by pertussis toxin. Mediators Inflamm (2014) 0.75
Osteopontin and fibronectin levels are decreased in vitreous of autoimmune uveitis and retinal expression of both proteins indicates ECM re-modeling. PLoS One (2011) 0.75
Spatiotemporal expression of osteopontin in the striatum of rats subjected to the mitochondrial toxin 3-nitropropionic acid correlates with microcalcification. Sci Rep (2017) 0.75
Increased Expression of Osteopontin in Retinal Degeneration Induced by Blue Light-Emitting Diode Exposure in Mice. Front Mol Neurosci (2016) 0.75
The P2X4 receptor is required for neuroprotection via ischemic preconditioning. Sci Rep (2016) 0.75
Osteopontin Impacts West Nile virus Pathogenesis and Resistance by Regulating Inflammasome Components and Cell Death in the Central Nervous System at Early Time Points. Mediators Inflamm (2017) 0.75
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol (2005) 24.22
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med (2010) 13.82
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Guillain-Barré syndrome. N Engl J Med (2012) 6.28
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet (2012) 4.25
Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood (2005) 4.17
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet (2012) 3.89
Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol (2008) 3.59
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol (2011) 3.52
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol (2009) 3.42
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol (2009) 3.37
MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology (2014) 3.27
Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol (2010) 3.26
Mutations in the small GTP-ase late endosomal protein RAB7 cause Charcot-Marie-Tooth type 2B neuropathy. Am J Hum Genet (2003) 3.22
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol (2011) 3.16
Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev (2008) 3.06
In vivo monitoring of inflammation after cardiac and cerebral ischemia by fluorine magnetic resonance imaging. Circulation (2008) 2.57
Polyclonal long-term repopulating stem cell clones in a primate model. Blood (2002) 2.53
Acute disseminated encephalomyelitis: an update. Arch Neurol (2005) 2.45
Guillain-Barré syndrome after exposure to influenza virus. Lancet Infect Dis (2010) 2.32
New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci (2002) 2.21
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol (2011) 2.19
Mechanical recanalization in basilar artery occlusion: the ENDOSTROKE study. Ann Neurol (2015) 2.16
Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol (2012) 2.12
Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med (2007) 2.06
Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology (2005) 2.06
The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood (2008) 2.01
Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain (2005) 1.92
Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J Cell Biochem (2007) 1.90
An osteopontin-NADPH oxidase signaling cascade promotes pro-matrix metalloproteinase 9 activation in aortic mesenchymal cells. Circ Res (2006) 1.88
Macrophages prevent hemorrhagic infarct transformation in murine stroke models. Ann Neurol (2012) 1.84
Chronic inflammatory demyelinating polyneuropathy. N Engl J Med (2005) 1.79
Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci U S A (2006) 1.79
Detrimental and beneficial effects of injury-induced inflammation and cytokine expression in the nervous system. Adv Exp Med Biol (2002) 1.78
Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease. Mult Scler (2012) 1.77
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol (2013) 1.76
Osteopontin modulates CD44-dependent chemotaxis of peritoneal macrophages through G-protein-coupled receptors: evidence of a role for an intracellular form of osteopontin. J Cell Physiol (2004) 1.76
Degeneration and regeneration of the peripheral nervous system: from Augustus Waller's observations to neuroinflammation. J Peripher Nerv Syst (2002) 1.73
More on PML in Patients Treated with Dimethyl Fumarate. N Engl J Med (2016) 1.73
Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. J Neuroimmunol (2004) 1.69
Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies. J Neurol Neurosurg Psychiatry (2012) 1.66
Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection. Trends Pharmacol Sci (2003) 1.65
Early MRI changes in a mouse model of multiple sclerosis are predictive of severe inflammatory tissue damage. Brain (2007) 1.63
Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Mult Scler (2011) 1.57
Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis. Neurology (2013) 1.56
Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Proc Natl Acad Sci U S A (2002) 1.55
Ultrathin PbS sheets by two-dimensional oriented attachment. Science (2010) 1.54
Immunopathogenesis and immunotherapy of multiple sclerosis. Nat Clin Pract Neurol (2006) 1.54
Thrombin-cleaved osteopontin regulates hemopoietic stem and progenitor cell functions through interactions with alpha9beta1 and alpha4beta1 integrins. Blood (2009) 1.53
Lower levels of N-acetylaspartate in multiple sclerosis patients with the apolipoprotein E epsilon4 allele. Arch Neurol (2003) 1.48
Effects of dimethyl fumarate on neuroprotection and immunomodulation. J Neuroinflammation (2012) 1.47
Towards individualised multiple-sclerosis therapy. Lancet Neurol (2005) 1.46
Neuromyelitis optica following human papillomavirus vaccination. Neurology (2012) 1.44
Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis. Arch Neurol (2009) 1.42
Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis. Expert Opin Pharmacother (2012) 1.40
Evidence for use of glatiramer acetate in multiple sclerosis. Lancet Neurol (2005) 1.40
Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a. Ann Neurol (2003) 1.39
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol (2010) 1.37
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol (2007) 1.36
Fingolimod is a potential novel therapy for multiple sclerosis. Nat Rev Neurol (2010) 1.36
Cell type-specific post-translational modifications of mouse osteopontin are associated with different adhesive properties. J Biol Chem (2007) 1.36
Acute disseminated encephalomyelitis: an acute hit against the brain. Curr Opin Neurol (2007) 1.34
Non-invasive induction of focal cerebral ischemia in mice by photothrombosis of cortical microvessels: characterization of inflammatory responses. J Neurosci Methods (2002) 1.33
Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome. Mult Scler (2013) 1.30
Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis. J Neuroimmunol (2009) 1.28
Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol (2013) 1.27
Unloading induces osteoblastic cell suppression and osteoclastic cell activation to lead to bone loss via sympathetic nervous system. J Biol Chem (2005) 1.27
Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: novel post-transcriptional, post-translational regulation. Clin Exp Metastasis (2006) 1.26
Phenotypes of the N88S Berardinelli-Seip congenital lipodystrophy 2 mutation. Ann Neurol (2005) 1.25
Enhancing remyelination in disease--can we wrap it up? Brain (2011) 1.25
Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs (2008) 1.25
Optical coherence tomography in parkinsonian syndromes. PLoS One (2012) 1.24
In vivo MRI of brain inflammation in human ischaemic stroke. Brain (2004) 1.24
Retinal damage in multiple sclerosis disease subtypes measured by high-resolution optical coherence tomography. Mult Scler Int (2012) 1.24
Cerebrospinal fluid of brain trauma patients inhibits in vitro neuronal network function via NMDA receptors. Ann Neurol (2009) 1.24
Animal models of multiple sclerosis--potentials and limitations. Prog Neurobiol (2010) 1.23
Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis (2009) 1.22
Autosomal dominant inherited neuropathies with prominent sensory loss and mutilations: a review. Arch Neurol (2003) 1.22
Accelerated development of aging-associated and instability-induced osteoarthritis in osteopontin-deficient mice. Arthritis Rheum (2009) 1.20
Osteopontin-deficient mice exhibit less inflammation, greater tissue damage, and impaired locomotor recovery from spinal cord injury compared with wild-type controls. J Neurosci (2007) 1.19
The complex world of oligodendroglial differentiation inhibitors. Ann Neurol (2011) 1.19
Expression genomics of cervical cancer: molecular classification and prediction of radiotherapy response by DNA microarray. Clin Cancer Res (2003) 1.19
Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders. Arch Neurol (2006) 1.17
New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol (2009) 1.15
Dendritic cells and dendritic-like microglia in focal cortical ischemia of the mouse brain. J Neuroimmunol (2002) 1.15
From bench to bedside--experimental rationale for immune-specific therapies in the inflamed peripheral nerve. Nat Clin Pract Neurol (2007) 1.14
Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch Neurol (2005) 1.13
Remyelinating strategies for the treatment of multiple sclerosis. Prog Neurobiol (2002) 1.12
Review of teriflunomide and its potential in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat (2009) 1.12
Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol (2010) 1.11
Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer. Oncogene (2005) 1.10
Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis. Lancet Neurol (2005) 1.10
Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. Arch Neurol (2007) 1.09
Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve (2004) 1.09
Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. Mult Scler (2012) 1.09
Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. Brain (2002) 1.08